In NSCLC, a therapeutic approach is differentiated with regard to mutant-EGFR and the development of resistance to anti-EGFR therapy through various mechanisms including gene line polymorphisms, secondary EGFR mutations, enhancement of alternate signalling pathways, and downstream signalling pathway protein mutations. Here, EGFR is linked to non-small cell lung carcinoma.